# Study of Radiolabeled Revumenib in Adults With Acute Leukemia

> **NCT05406817** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Acute Leukemia

## Interventions

- **DRUG:** Revumenib

## Key facts

- **NCT ID:** NCT05406817
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-05
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05406817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05406817, "Study of Radiolabeled Revumenib in Adults With Acute Leukemia". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05406817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*